FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Equine Vet J / The proteomic differences and expression of fatty acid-bindi...
Equine veterinary journal2025; doi: 10.1111/evj.14538

The proteomic differences and expression of fatty acid-binding protein 6 (FABP6) associated with gastrointestinal injury in horses with oral administration of a clinical dose of phenylbutazone.

Abstract: Phenylbutazone (PBZ) can potentially induce gastrointestinal ulceration, and early detection of PBZ-induced gastroenteropathy will be useful for the diagnosis, treatment, and prevention of PBZ toxicity. Objective: To identify putative proteins associated with equine gastric ulcer syndrome after clinical dose (4.4 mg/kg) administration of PBZ by proteomic study. Methods: In vivo experiments. Methods: Proteomic analysis using LC-MS/MS compared protein expression in serum and faeces of seven PBZ-treated horses with seven placebo-treated controls, and a novel putative biomarker was validated via enzyme-linked immunosorbent assay. Results: Differentially expressed proteins (DEPs) analysis on 5298 serum annotated proteins and 3538 faecal annotated proteins using the DESeq2 were performed between the control and treatment of EGUS groups. The results showed a list of 226 and 181 significant proteins in serum and faecal samples, respectively with a p adjust value <0.05. The proteomic serum and faeces samples were integrated into STITCH to illustrate PBZ interaction with bile acid homeostasis. FABP6 was significantly increased in PBZ-treated horses. The serum FABP6 concentration in the treatment group on Day 8 (1.80 ± 0.37 ng/mL) was higher than on Day 0 (1.15 ± 0.33 ng/mL, p = 0.01, 95% CI [-1.07, -0.25]). On Day 8, the serum FABP6 concentration in the treatment group was also higher than the control group (1.20 ± 0.48 ng/mL; p = 0.02, 95% CI [-1.10, -0.11]). Conclusions: Validation of all expressed proteins is a main limitation. Conclusions: Administration of PBZ at a clinical dose of 4.4 mg/kg twice daily for 7 days may cause gastric mucosal damage. PBZ treatment increased the expression of SLC10A1 and FABP6, suggesting that early gastric mucosal injury may be linked to the bile acid pathway. Bile acids could potentially exacerbate PBZ-induced EGUS.
© 2025 The Author(s). Equine Veterinary Journal published by John Wiley & Sons Ltd on behalf of EVJ Ltd.
Get Full Text
Publication Date: 2025-05-22 PubMed ID: 40405508DOI: 10.1111/evj.14538Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research investigates the impact of clinical doses of phenylbutazone, a common equine medication, on gastrointestinal health of horses, and identifies potential biomarkers that could be used for early detection of adverse effects.

Objective

The study aims to identify proteins that could be associated with equine gastric ulcer syndrome (EGUS) following an administration of clinically recommended dose of phenylbutazone (PBZ), a nonsteroidal anti-inflammatory drug (NSAID) often used in horses.

Methods

  • The researchers administered PBZ to seven horses, and a placebo to a control group of seven other horses. Afterward, they analyzed and compared the protein expression in the serum and faeces of both groups using Liquid Chromatography with tandem mass spectrometry (LC-MS/MS).
  • For validation of a novel potential biomarker, they used an enzyme-linked immunosorbent assay (ELISA), a commonly used laboratory test to measure the concentration of substances such as proteins and antibodies in biological samples.

Results

  • The team identified 226 proteins in the serum and 181 significant proteins in the faecal samples that had differential expression in the treated horses compared to the control group.
  • The fatty acid-binding protein 6 (FABP6) was found to be significantly increased in horses treated with PBZ.
  • On the 8th day of administration, the FABP6 concentration was higher than on day 0 and also higher than the control group.

Conclusions

  • The study concluded that PBZ treatment at a clinical dose could cause gastric mucosal damage.
  • The increase in expression of SLC10A1 and FABP6 suggests the potential role of bile acid pathway in early gastric mucosal injury caused by PBZ.
  • Bile acids, necessary for digestion and absorption of fats, could exacerbate PBZ-induced EGUS. As such, monitoring the levels of FABP6 and SLC10A1 in horses could potentially serve as an early warning sign of PBZ-induced gastric injury.
  • However, one major limitation pointed out by the authors is the lack of validation of all expressed proteins in this study.

Cite This Article

APA
Vinijkumthorn R, Prapaiwan N, Chotikaprakal T, Prompiram P, Phaonakrop N, Roytrakul S, Tesena P. (2025). The proteomic differences and expression of fatty acid-binding protein 6 (FABP6) associated with gastrointestinal injury in horses with oral administration of a clinical dose of phenylbutazone. Equine Vet J. https://doi.org/10.1111/evj.14538

Publication

Equine veterinary journal
ISSN: 2042-3306
NlmUniqueID: 0173320
Country: United States
Language: English

Researcher Affiliations

Vinijkumthorn, Ruethaiwan
  • Department of Clinical Science and Public Health, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand.
Prapaiwan, Nawarus
  • Department of Clinical Science and Public Health, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand.
Chotikaprakal, Thanapon
  • Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand.
Prompiram, Phirom
  • The Monitoring and Surveillance Center for Zoonotic Diseases in Wildlife and Exotic Animals, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand.
Phaonakrop, Narumon
  • Functional Proteomics Technology Laboratory, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Thani, Thailand.
Roytrakul, Sittiruk
  • Functional Proteomics Technology Laboratory, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Thani, Thailand.
Tesena, Parichart
  • Department of Clinical Science and Public Health, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand.

Grant Funding

  • FF-131/2567 / Mahidol University

References

This article includes 41 references
  1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin‐like drugs.. Nat New Biol 1971;231(25):232–235.
    doi: 10.1038/newbio231232a0google scholar: lookup
  2. Banse HE, Cribb AE. Review of nonsteroidal anti‐inflammatory drug selection in horses.. Proc Am Assoc Equine Pract 2015;61:532–536.
  3. Karcher LF, Dill SG, Anderson WI, King JM. Right dorsal colitis.. J Vet Intern Med 1990;4(5):247–253.
    doi: 10.1111/j.1939-1676.1990.tb03117.xgoogle scholar: lookup
  4. MacAllister CG, Morgan SJ, Borne AT, Pollet RA. Comparison of adverse effects of phenylbutazone, flunixin meglumine, and ketoprofen in horses.. J Am Vet Med Assoc 1993;202(1):71–77.
  5. Noble G, Edwards S, Lievaart J, Pippia J, Boston R, Raidal SL. Pharmacokinetics and safety of single and multiple oral doses of meloxicam in adult horses.. J Vet Intern Med 2012;26(5):1192–1201.
    doi: 10.1111/j.1939-1676.2012.00976.xgoogle scholar: lookup
  6. MacKay RJ, French TW, Nguyen HT, Mayhew IG. Effects of large doses of phenylbutazone administration to horses.. Am J Vet Res 1983;44(5):774–780.
  7. Tesena P, Yingchutrakul Y, Roytrakul S, Wongtawan T, Angkanaporn K. Serum protein expression in equine glandular gastric disease (EGGD) induced by phenylbutazone.. J Vet Med Sci 2019;81(3):418–424.
    doi: 10.1292/jvms.18-0679google scholar: lookup
  8. Murray MJ. Equine model of inducing ulceration in alimentary squamous epithelial mucosa.. Dig Dis Sci 1994;39:2530–2535.
    doi: 10.1007/bf02087686google scholar: lookup
  9. Shawaf T, El‐Deeb WM, Elgioushy M. The contribution of specific and nonspecific biomarkers in diagnosis of equine gastric ulcer syndrome (EGUS) under field condition.. J Equine Vet Sci 2020;84:102853.
    doi: 10.1016/j.jevs.2019.102853google scholar: lookup
  10. Barletta M, Quandt J, Reed R. Equine anesthesia and pain management.. 1st ed. Boca Raton, FL: CRC Press; 2023.
    doi: 10.1201/9780429190940google scholar: lookup
  11. Clark‐Price S, Mama K. Equine anesthesia and co‐existing disease.. 1st ed. Hoboken, NJ: Wiley‐Blackwell; 2022.
  12. Sykes BW, Hewetson M, Hepburn RJ, Luthersson N, Tamzali Y. European College of Equine Internal Medicine consensus statement‐equine gastric ulcer syndrome in adult horses.. J Vet Intern Med 2015;29:1288–1299.
    doi: 10.1111/jvim.13578google scholar: lookup
  13. Banse HE, Andrews FM. Equine glandular gastric disease: prevalence, impact and management strategies.. Vet Med (Auckl) 2019;10:69–76.
    doi: 10.2147/vmrr.s174427google scholar: lookup
  14. Lowry O, Roserough N, Farr A, Randall R. Protein measurement with the folin phenol reagent.. J Biol Chem 1951;193:265–275.
  15. Tyanova S, Temu T, Cox J. The MaxQuant computational platform for mass spectrometry‐based shotgun proteomics.. Nat Protoc 2016;11(12):2301–2319.
    doi: 10.1038/nprot.2016.136google scholar: lookup
  16. UniProt Consortium. UniProt: the universal protein knowledgebase in 2023.. Nucleic Acids Res 2023;51(D1):D523–D531.
    doi: 10.1093/nar/gkac1052google scholar: lookup
  17. Howe E, Sinha R, Schlauch D, Quackenbush J. RNA‐seq analysis in MeV.. Bioinformatics 2011;27(22):3209–3210.
    doi: 10.1093/bioinformatics/btr490google scholar: lookup
  18. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA‐seq data with DESeq2.. Genome Biol 2014;15:550.
    doi: 10.1186/s13059-014-0550-8google scholar: lookup
  19. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing.. J Royal Stat Soc Ser B 1995;57(1):289–300.
    doi: 10.1111/j.2517-6161.1995.tb02031google scholar: lookup
  20. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M. The KEGG resource for deciphering the genome.. Nucleic Acids Res 2004;32:D277–D280.
    doi: 10.1093/nar/gkh063google scholar: lookup
  21. Kanehisa M, Sato Y, Morishima K. BlastKOALA and GhostKOALA: KEGG tools for functional characterization of genome and metagenome sequences.. J Mol Biol 2016;428:726–731.
    doi: 10.1016/j.jmb.2015.11.006google scholar: lookup
  22. Kuhn M, von Mering C, Campillos M, Jensen LJ, Bork P. STITCH: interaction networks of chemicals and proteins.. Nucleic Acids Res 2008;36:D684–D688.
    doi: 10.1093/nar/gkm795google scholar: lookup
  23. Walz DA, Wider MD, Snow JW, Dass C, Desiderio DM. The complete amino acid sequence of porcine gastrotropin, in ileal protein which stimulates gastric acid and pepsinogen secretion.. J Biol Chem 1988;263(28):14189–14195.
  24. Chiang JYL. Recent advances in understanding bile acid homeostasis.. F1000Res 2017;6:2029.
    doi: 10.12688/f1000research.12449.1google scholar: lookup
  25. Zhao X, Liu Z, Sun F, Yao L, Yang G, Wang K. Bile acid detection techniques and bile acid‐related diseases.. Front Physiol 2022;13:826740.
    doi: 10.3389/fphys.2022.826740google scholar: lookup
  26. Režen T, Rozman D, Kovács T, Kovács P, Sipos A, Bai P. The role of bile acids in carcinogenesis.. Cell Mol Life Sci 2022;79(5):243.
    doi: 10.1007/s00018-022-04278-2google scholar: lookup
  27. Park MJ, Kim KH, Kim HY, Kim K, Cheong J. Bile acid induces expression of COX‐2 through the homeodomain transcription factor CDX1 and orphan nuclear receptor SHP in human gastric cancer cells.. Carcinogenesis 2008;29(12):2385–2393.
    doi: 10.1093/carcin/bgn207google scholar: lookup
  28. Zhao A, Wang S, Chen W, Zheng X, Huang F, Han X. Increased levels of conjugated bile acids are associated with human bile reflux gastritis.. Sci Rep 2020;10(1):11601.
    doi: 10.1038/s41598-020-68393-5google scholar: lookup
  29. Satoh H, Akiba Y, Urushidani T, Kaunitz JD. Gastroparesis worsens indomethacin‐induced gastric antral ulcers by bile reflux via activation of 5‐HT3 and dopamine D2 receptors in mice.. Dig Dis Sci 2023;68(10):3886–3901.
    doi: 10.1007/s10620-023-08086-xgoogle scholar: lookup
  30. Zhou Y, Dial EJ, Doyen R, Lichtenberger LM. Effect of indomethacin on bile acid‐phospholipid interactions: implication for small intestinal injury induced by nonsteroidal anti‐inflammatory drugs.. Am J Physiol Gastrointest Liver Physiol 2010;298(5):G722–G731.
    doi: 10.1152/ajpgi.00387.2009google scholar: lookup
  31. Chan CPY, Wan TSM, Watkins KL, Pelsers MMAL, Van Der Voort D, Tang FPW. Rapid analysis of fatty acid‐binding proteins with immunosensors and immunotests for early monitoring of tissue injury.. Biosens Bioelectron 2005;20(12):2566–2580.
    doi: 10.1016/j.bios.2004.09.028google scholar: lookup
  32. Pelsers MMAL, Hermens WT, Glatz JFC. Fatty acid‐binding proteins as plasma markers of tissue injury.. Clin Chim Acta 2005;352(1–2):15–35.
    doi: 10.1016/j.cccn.2004.09.001google scholar: lookup
  33. Relja B, Szermutzky M, Henrich D, Maier M, De Haan JJ, Lubbers T. Intestinal‐FABP and liver‐FABP: novel markers for severe abdominal injury.. Acad Emerg Med 2010;17(7):729–735.
    doi: 10.1111/j.1553-2712.2010.00792.xgoogle scholar: lookup
  34. Nieto JE, Aldridge BM, Beldomenico PM, Aleman M, Snyder JR. Characterization of equine intestinal fatty acid binding protein and its use in managing horses with colic.. Am J Vet Res 2005;66(2):223–232.
    doi: 10.2460/ajvr.2005.66.223google scholar: lookup
  35. McKillop IH, Girardi CA, Thompson KJ. Role of fatty acid binding proteins (FABPs) in cancer development and progression.. Cell Signal 2019;62:109336.
    doi: 10.1016/j.cellsig.2019.06.001google scholar: lookup
  36. Defize J, Wider MD, Walz D, Hunt RH. Isolation and partial characterization of gastrotropin from canine ileum: further studies of the parietal and chief cell response.. Endocrinology 1988;123(5):2578–2584.
    doi: 10.1210/endo-123-5-2578google scholar: lookup
  37. Gantz I, Nothwehr SF, Lucey M, Sacchettini JC, DelValle J, Banaszak LJ. Gastrotropin: not an enterooxyntin but a member of a family of cytoplasmic hydrophobic ligand binding proteins.. J Biol Chem 1989;264(34):20248–20254.
  38. Niu S, Fei M, Cheng C, Yan M, Gao S, Chen M. Altered β‐1,4‐galactosyltransferase I expression during early inflammation after spinal cord contusion injury.. J Chem Neuroanat 2008;35(3):245–256.
    doi: 10.1016/j.jchemneu.2008.01.002google scholar: lookup
  39. Maisi P, Koivunen AL, Rantala AR, Turgut K. Β‐Glucuronidase and trypsin inhibitor capacity of tracheal lavage fluid as indicators of seasonal airway irritation in the horse.. Equine Vet J 1994;26(5):385–391.
    doi: 10.1111/j.2042-3306.1994.tb04408.xgoogle scholar: lookup
  40. Jones SL, Sharief Y, Chilcoat CD. Signaling mechanism for equine neutrophil activation by immune complexes.. Vet Immunol Immunopathol 2001;82(1–2):87–100.
    doi: 10.1016/s0165-2427(01)00350-6google scholar: lookup
  41. Vinijkumthorn R, Bauck AG, Vidyasagar S, Freeman DE. Nonsteroidal antiinflammatory drugs reduce anion secretion and increase apoptosis in equine colonic mucosa ex vivo.. Am J Vet Res 2023;85(1):ajvr.23.08.0182.
    doi: 10.2460/ajvr.23.08.0182google scholar: lookup

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,075 horse owners like you who receive our email updates on horse health and nutrition.